23.86 USD
-0.25 (-1.04%)
ChartMill assigns a Buy % Consensus number of 85% to RARE. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 83.74. This target is 250.97% above the current price.
- RARE was analyzed by 27 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about RARE.
- In the previous month the buy percentage consensus was at a similar level.
- RARE was analyzed by 27 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-05 | Guggenheim | Maintains | Buy -> Buy |
| 2026-01-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-02 | B of A Securities | Maintains | Buy -> Buy |
| 2025-12-30 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-12-30 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-30 | Baird | Maintains | Outperform -> Outperform |
| 2025-12-30 | Jefferies | Maintains | Buy -> Buy |
| 2025-11-24 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-05 | TD Cowen | Maintains | Buy -> Buy |
| 2025-11-05 | Truist Securities | Maintains | Buy -> Buy |
| 2025-09-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-05 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-08-08 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-06 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-07-14 | Wedbush | Maintains | Neutral -> Neutral |
| 2025-07-14 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-10 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-06-20 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-05-28 | William Blair | Initiate | Outperform |
| 2025-05-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-03-27 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-03-17 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-02-26 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-02-18 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-02-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-01-13 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-01-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-12-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
ULTRAGENYX PHARMACEUTICAL IN / RARE FAQ
What is the price target for RARE stock?
27 analysts have analysed RARE and the average price target is 83.74 USD. This implies a price increase of 250.97% is expected in the next year compared to the current price of 23.86.
Can you provide the consensus rating for ULTRAGENYX PHARMACEUTICAL IN stock?
The consensus rating for ULTRAGENYX PHARMACEUTICAL IN (RARE) is 85.1852 / 100 . This indicates that analysts generally have a positive outlook on the stock.